We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

AspenBio Launches Lateral Flow Division

By Labmedica staff writers
Posted on 18 Mar 2004
The launch of a Lateral Flow Division for the development, manufacturing, and distribution of immunochromatographic rapid tests has been announced by AspenBio, Inc. (Castle Rock, CO, USA).

Immunochromatographic tests are used to determine the presence or absence of minute quantities of target analyte in various types of samples within a few minutes and are particularly useful as clinical diagnostic tools. One example is the home pregnancy test. The tests can save clinicians up to 12 hours of laboratory time by replacing immunoblotting in some cases. AspenBio has developed tests for insulin, luteinizing hormone, growth hormone, alpha fetoprotein (AFP), mouse IgG, and thyroid stimulating hormone.

"Adding this division to AspenBio's capabilities is in response to requests from universities, research facilities, and veterinarians,” said Dr. Mark Colgin, chief scientist. "These initial devices, in addition to others currently being developed, will assist technicians, scientists, and doctors with reduced analytical costs and shortened turnaround times.”




Related Links:
AspenBio

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Immunofluorescence Analyzer
IFA System
Hematology Consumables
Bioblood Devices

Latest Industry News

New NHS Partnership Expands Access to Epigenetic CNS Tumor Classifiers
18 Mar 2004  |   Industry

Fujirebio Expands Access to Automated Blood-Based Neurology Testing in Canada
18 Mar 2004  |   Industry

Natera ctDNA Test to Support Response Monitoring in Solid Tumor Trial
18 Mar 2004  |   Industry